Induction therapy for cryptococcal meningitis includes which agent?

Induction therapy for cryptococcal meningitis includes which agent?

• A. Flucytosine
• B. Fluconazole
• C. Voriconazole
• D. Echinocandin

Answer: (A)

Rapid, early clearance of cryptococcus from the CSF is achieved with a potent induction regimen that combines a fast-acting fungicidal partner with a companion drug. Flucytosine is included in induction because, when used with amphotericin B, it works synergistically to accelerate fungal kill and CSF sterilization, which improves outcomes. The other agents aren’t used for induction: fluconazole is typically reserved for consolidation and maintenance due to its fungistatic nature and slower clearance from the CNS; voriconazole hasn’t shown the same level of efficacy in induction; echinocandins have poor activity against Cryptococcus and are not used in induction. After induction, fluconazole is used for consolidation and maintenance to prevent relapse.

Rapid, early clearance of cryptococcus from the CSF is achieved with a potent induction regimen that combines a fast-acting fungicidal partner with a companion drug. Flucytosine is included in induction because, when used with amphotericin B, it works synergistically to accelerate fungal kill and CSF sterilization, which improves outcomes. The other agents aren’t used for induction: fluconazole is typically reserved for consolidation and maintenance due to its fungistatic nature and slower clearance from the CNS; voriconazole hasn’t shown the same level of efficacy in induction; echinocandins have poor activity against Cryptococcus and are not used in induction. After induction, fluconazole is used for consolidation and maintenance to prevent relapse.